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Abstract
Background
Optimum efficiency of the folate pathway is considered essential for adequate ovarian func-
tion. 677 C>T substitution in the 5, 10-methylene tertrahydrofolatereductase (MTHFR) gene
compromises activity of the MTHFR enzyme by about 50%. The significance of correlation
between 677C>T substitution and PCOS remains dubious due to the low power of pub-
lished studies.
Methods and Results
We analyzedMTHFR 677 C>T site in ethnically two different PCOS case-control groups
(total 261 cases and 256 controls) from India. The data analysis revealed a lack of associa-
tion between this polymorphism and PCOS [OR = 1.11 (95%CI = 0.71–1.72), P = 0.66].
Group-wise analysis on the basis of ethnicity also revealed no association in any of the eth-
nic groups [Indo-Europeans, P = 1; Dravidians, P = 0.70]. Homocysteine levels did not differ
significantly between cases (15.51 μmol/L, SD = 2.89) and controls (15.89 μmol/L, SD =
2.23). We also undertook a meta-analysis on 960 cases and 1028 controls, which sug-
gested a significant association of the substitution with PCOS in the dominant model of
analysis (OR = 1.47 (95%CI = 1.04–2.09), P = 0.032]. Trial sequential analysis corroborated
findings of the traditional meta-analysis. However, we found that the conclusions of meta-
analysis were strongly influenced by studies that deviated from the Hardy Weinberg equilib-
rium. A careful investigation of each study and a trial sequential analysis suggested that
677 C>T substitution holds no clinical significance in PCOS in most of the populations.
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Conclusion
In conclusion,MTHFR 677 C>T polymorphism does not affect PCOS risk in India. The asso-
ciation seen in the meta-analysis is due to an outlier study and studies showing deviation
from the Hardy Weinberg equilibrium.
Introduction
Polycystic ovarian syndrome (PCOS) is the most widespread form of female infertility. Quoted
prevalence of PCOS ranges from 5 to 25% [1–2]. The hormonal condition in polycystic women
presents an excessive production of androgens, which disturbs menstrual cycle and ovulation,
leading to primary or secondary infertility. This problem impairs female fertility to varying
degrees and affects approximately 10% of women in India, but the incidence is on a sharp rise
[3,4]. Around 4% of unselected population of reproductive age and 7% of the Caucasian popu-
lation is believed to have this syndrome [5]. PCOS shows a heterogeneous mode of presenta-
tion characterized by metabolic disorder with anovulation, chronic anovulatory cycles,
oligomenorrhea, endometrial dysplasia, non-insulin dependent diabetes mellitus (Type II),
dyslipidaemia (hyper), hypertension, sub-fertility and enlarged cystic ovaries [6]. In 2003, the
Rotterdam consensus of the American Society for Reproductive Medicine/ European Society of
Human Reproduction and Embryology stated that polycystic ovaries, oligo/anovulation and
hyperandrogenism are the most detectable traits of PCOS [7].
Etiology of PCOS remains largely unknown; however, the syndrome is thought to be multi-
factorial with hyperinsulinemia and lifestyle factors being the prominent contributing factors.
Questions about the possible effect of folic acid on ovarian function were raised in the late
1960s, with the finding that deficiency/excess of folates partially inhibited ovulation in imma-
ture super-ovulated rats [8]. Later, a research group demonstrated that ovarian biopsies from
folate deprived monkeys showed degeneration of Graffian follicles with an increase in atretic
and cystic follicles, accompanied by a depletion of granulosa cells and reduction or even
absence of corpora lutea [9]. The above suggested a critical importance of one carbon metabo-
lism in ovarian function and dysfunction. Since folate cycle and homocysteine-methionine
cycle run in conjugation, alterations in the folate cycle may disturb homocysteine-methionine
balance and maintenance of the methyl pool [10]. There is now sufficient evidence supporting
high homocysteine levels in PCOS cases [11–13]. Interestingly, homocysteine level returned to
normal following folic acid supplementation [13]. This makes methylenetetrahydrofolate
reductase (MTHFR) an important gene for investigation in PCOS as decreased efficiency of
folate/homocysteine pathway could increase the risk.
It has been experimentally shown that a functional substitution, 677 C>T (alanine is substi-
tuted by valine, rs1801133), in theMTHFR gene compromises activity of this gene and the
folate pathway by about 50% [14–16]. There are reports of a significantly elevated PCOS risk
associated with mutant genotypes at this locus [17–18]. On the other hand, a higher frequency
of the supposed risk allele (T) has been reported in controls [19–20]. Most of the studies that
negate a correlation between 677 C>T and PCOS severely lack statistical power required to
support the inference [19–25]. Apart from a few case-control studies based on small sample
sizes, at least three meta-analyses have previously investigated the importance of this polymor-
phism in PCOS [26–28]. We undertook the present case-control study on a larger set of sam-
ples so as to draw conclusions with adequate power. Further, we recruited two ethnically
different case-control groups to evaluate significance of ethnic variations on the correlation.
MTHFR 677 C>T Polymorphism and PCOS
PLOSONE | DOI:10.1371/journal.pone.0151510 March 16, 2016 2 / 15
Competing Interests: The authors have declared
that no competing interests exist.
We also undertook a trail sequential analysis to critically examine the inference and power of
the study and validate the findings of the traditional meta-analysis.
Materials and Methods
Study population
This study was approved by the Institutional Human Ethics Committee of the Maaruthi Medi-
cal Centre and Hospitals, Erode, Tamil Nadu and that of the CSIR-Central Drug Research
Institute, Lucknow, Uttar Pardesh. We calculated the sample size using G power calculator,
assuming a 10% frequency of the polymorphism (already reported in Indian populations),
p = 0.05, study power of 90% and effect size of 0.3. This suggested a sample size of 234 (117
cases and 117 controls). We recruited 517 subjects with or without PCOS from the Maaruthi
Medical Center and Hospitals, Erode, Tamil Nadu and the Institute of Medical Sciences, Bana-
ras Hindu University, Varanasi. Relevant details about the subjects such as age, height, weight
and age at marriage were noted. The inclusion criteria of patients were based on the Rotterdam
Revised 2003 (2 out of 3) diagnosis guidelines. This included the presence of two out of the fol-
lowing three features (after the exclusion of related disorders): (1) Oligo- or an-ovulation, (2)
Clinical and/or biochemical signs of hyperandrogenism, and (3) Polycystic ovaries. Hyper-
androgenism was diagnosed by measuring serum testosterone, androstenedione, and DHEAS
(Dehyroepiandrosteronesulphate) levels in the early follicular phase and by looking at the pat-
tern and extent of terminal hair growth (hirsutism). Menstrual history of the patients was
recorded to diagnose oligo-/ameno-rrhea. Ovarian morphology was studied by transvaginal
ultrasonography to find if enlarged ovaries with at least 12 peripherally arranged immature fol-
licles, a characteristic feature of PCOS, were seen.
We recruited 261 patients (168 from the Dravidian population and 93 from the Indo-Euro-
pean population) following the above inclusion criteria. The exclusion criteria consisted of the
presence of congenital adrenal hyperplasia, Cushing’s syndrome, thyroid dysfunction or hyper-
prolactinemia. The patients were categorized in obese and non-obese groups according to the
World Health Organization (WHO) criteria. Women having BMI in the range of 27.3–32.3
(overweight) and>32.3 (obese) were included in the obese group while women having BMI in
the range of 19.1–25.8 (Normal) and 25.8–27.3 (Marginally overweight) were included in the
non-obese group [29]. The BMI values for the Indo-European subjects could not be collected;
therefore, this classification was applied to the Dravidian group only. Accordingly, in the Dra-
vidian patient group, 144/169 (85.2%) fell in the obese and 25/169 (14.8%) fell in the non-
obese category. The BMI in the hyperandrogenic group (36.91±5.18) was significantly higher
in comparison to the normoandrogenic (29.39±4.0) group (P = 0.0001).
Two hundred fifty six ethnically matched control samples (comprising of 156 subjects from
the Dravidian population and 100 from the Indo-European population) were collected from
proven fertile women who volunteered to participate in the study. The controls were recruited
according to the defined inclusion criteria of proven fertility with normal menstrual cycle and
ovarian morphology, but no history of sub-fertility treatment. Peripheral blood samples (3–5
ml) of the patients and controls were collected for genetic analysis. Informed written consents
were obtained from all participants. Homocysteine level in serum samples was measured using
an enzymatic test based kit manufactured by Diazyme Laboratories (USA).
DNA isolation
Genomic DNA was isolated from peripheral blood samples according to the protocol described
in our previous study [30]. DNA concentration was determined using a spectrophotometric
method by reading absorbance at 260 nm, followed by dilution to 10 ng (working
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concentration) in the standard TE buffer. The quality of DNA preparation was evaluated on
1% agarose gel.
PCR amplification and genetic analyses
677C>T region of theMTHFR gene was amplified using primers and the protocol published
in our earlier study [31]. Briefly, PCR was carried out in a reaction volume of 10 μl each in thin
walled tubes, consisting of 1.0 μl of PCR buffer (10X), 1.0 μl of MgCl2 (25 mM), 1.0 μl of
dNTPs (10 mM), 2.0 pM of each of the forward (5’ CATCCCTATTGGCAGGTTACCC 3’)
and reverse (5’ GGGAAGAACTCAGCGAACTCAG 3’) primers, 1.0 unit of Taq DNA poly-
merase enzyme (Applied Biosystems) and 40 ng of genomic DNA. PCR amplification was car-
ried out using the ABI Veriti thermal cycler (Applied Biosystems, USA) with the following
conditions; denaturation at 95°C for 10 minutes followed by 35 cycles of denaturation at 95°C
for 30 seconds, annealing at 63°C for 30 seconds and polymerization at 72°C for 40 sec, and a
final stage of polymerization at 72°C for 7 minutes. The amplicons were directly sequenced
using BigDyeTM chain termination chemistry on the ABI 3730 DNA analyzer (Applied Biosys-
tems, USA)[32]. Multiple alignment and sequence analyses were undertaken using the AutoAs-
sembler Software (Applied Biosystems, USA).
Statistical analyses
Genotype data for the control group were analyzed for fitness in the Hardy Weinberg (HW)
equilibrium. All statistical analyses were performed using the SPSS software (www.spss.com).
The frequency of the major and minor alleles was compared between cases and controls using
the chi-square (χ2) test. Pooled data for all cases (Indo-European and Dravidian) were com-
pared with controls, followed by the comparison of cases and controls within each group. The
two-sided P value of less than 0.05 (95% level of confidence) was considered significant for sta-
tistical inference.
Meta Analysis
Literature search. A robust search in PubMed (www.pubmed.com), Google Scholar
(scholar.google.co.in) and ScienceDirect (www.sciencedirect.com) databases was conducted
using the keywords such as ‘PCOS’, ‘MTHFR’, ‘677C>T’ polymorphism’ and ‘polycystic ova-
ries’ in various combinations. The search terms were kept broad to identify all relevant articles
and the last search was performed on the 28th of February 2015. The initial screening was done
to look forMTHFR 677 C>T polymorphism data and the full text articles of relevant studies
were obtained. The corresponding author was contacted in case a full text article was not acces-
sible. Only fifteen studies containing data on 677 C>T polymorphism in PCOS could be iden-
tified (Fig 1).
Inclusion and exclusion criteria. Each article was thoroughly explored to extract the
required information such as the purpose and design of study, data presentation, genotyping
method used, inclusion and exclusion criteria adopted for recruiting cases and controls. The
studies were further filtered to fit an inclusion criteria that (i) each trial was an independent
case-control study, (ii) all the studies had a similar purpose of investigating the correlation of
677 C>T polymorphism with PCOS, (iii) enough information had been provided for the calcu-
lation of odds ratio (OR), (iv) SNP genotyping was done at the high resolution level, (v) selec-
tion of patients was done according to the standard and reliable diagnostic parameters. The
studies not providing enough information (raw data) and those providing poor description of
subject recruitment and analysis, were excluded.
MTHFR 677 C>T Polymorphism and PCOS
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Fig 1. PRISMA flow diagram. The flow diagrams shows screening of literature and selection of studies for meta-analysis.
doi:10.1371/journal.pone.0151510.g001
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Raw data extraction. Genotype data for the target polymorphism were extracted using the
standard extraction form, and wherever necessary, the genotype frequencies were re-calculated
to ensure homogeneous data presentation. The data were tabulated with specific details regard-
ing the first author, year of publication, sample size, ethnicity of study population, and allele
and genotype frequencies. Details required for standard reporting in systematic reviews and
meta-analysis have been presented in PRISMA checklist (S1 Table) and meta-analysis on
genetic association studies checklist (S2 Table). To ensure the correct representation, JC and SS
performed data extraction using two independent forms and submitted it to the senior author
of this article.
Quantitative data synthesis. Meta-analysis was conducted using the Comprehensive
Meta Analysis software (version 2). We chose OR as the effect size to find PCOS risk associated
with the rare genotypes (CT and TT). Raw data for each study were fed into software for calcu-
lation of the respective OR and p value. Heterogeneity test was performed using the chi-square
based ‘Q’ test suggested by Cochran [33] and the inconsistency value (I2) given by Higgins
[34]. In the presence of heterogeneity, random effects model was used while in the case of
homogeneity, fixed effect model was used. An analysis model was chosen on the basis of the
spread (distribution) of effect sizes and the level of heterogeneity. Since the test for heterogene-
ity suffers from low power, p values less than 0.10 were considered to be statistically significant.
High-resolution plots were generated corresponding to OR and CI at 95% for fixed as well as
random effects models. To check how the OR changed with subsequent addition of studies, a
cumulative analysis was performed. Analyses using recessive and co-dominant models were
also undertaken to thoroughly investigate the relationship between 677 C>T substitution and
PCOS.
The data from each study were tested for fitness in the Hardy-Weinberg equilibrium using
the chi-square method. The impact of assumptions on the robustness of inference was judged
by sensitivity analysis. Publication bias was assessed using the funnel plot of precision by log
odds ratio and calculated quantitatively using various statistical tools, such as Egger’s regres-
sion intercept, Duvall and Tweedie trim and fill procedure, Classic fail-safe ‘N’ and Orwin fail-
safe ‘N’. Funnel plot was generated for the picturesque analysis of publication bias.
Trial sequential analysis (TSA)
Ameta-analysis is prone to systematic (bias) or random errors (play of chance) due to dis-
persed data and repeated significance testing. Bias from trials with low methodological quality,
publication bias and small trial bias may result in false P-value. Therefore, we used trial sequen-
tial analysis (TSA) for the calculation of required information size (number of samples) for reli-
ability of meta-analysis [35]. Some previous studies have shown that the outcomes of TSA are
more reliable than those of the traditional meta-analysis [36–38]. We calculated the required
information size by considering an overall type–I error of 5% and type-II error of 20%. TSA
plotted a two-sided graph where red straight lines indicate significance boundaries of the con-
ventional meta-analysis, the blue line shows cumulative Z-score, and red lines sloping inwards
represent trial sequential monitoring boundaries with adjusted P-values.
Results
Clinical data
A comparative account of clinical data of patients falling in the hyper- and normo-androgenic
groups is presented in Table 1. Almost all clinically relevant measures were significantly ele-
vated in the hyper-androgenic group in comparison to the normo-androgenic group. The clini-
cal values were also compared between patients with wild type (CC) and mutant (CT+TT)
MTHFR 677 C>T Polymorphism and PCOS
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genotypes. Cross-classification analysis of hyper- or normo-androgenism versus genotypes
(CC and CT+TT) did not show any significant association between the two (Table 2). The
average homocysteine level in the cases (15.51 μmol/L, SD = 2.89) was not significantly differ-
ent (P = 0.64) from the controls (15.89 μmol/L, SD = 2.23).
Case-control study
The genotype data for the control group fitted well in the Hardy Weinberg equilibrium (Exact
test, p = 1.00). No significant association between 677C>T substitution and PCOS was
observed in the pooled data of all cases versus controls (OR = 1.11, 95% CI = 0.71–1.72,
P = 0.66). Similarly, in discrete analysis for each group (Indo-European and Dravidian), the p
Table 1. Distribution and comparison of various clinical parameters between hyper- and normo-androgenic groups.
Clinical
Parameters
Hyperandrogenism
(N = 104) (Mean±SD)
Normoandrogenism
(N = 157) (Mean±SD)
Comparison (P
value)
Inference
Age (years) 29.17±5.15 30.11±5.47 0.3337 The mean age in hyperandrogenism is lower than
the mean age in normoandrogenism.
Height (cm) 151.97±2.83 151.46±3.05 0.2699 The mean height in hyperandrogenism is almost
similar to the mean height in normoandrogenism.
Weight (kg) 84.59±11.00 66.81±10.32 0.0001 The mean weight in hyperandrogenism is higher than
the mean weight in normoandrogenism.
FSH (mIU) 5.98±1.22 5.56±1.04 0.0177 The mean FSH level in hyperandrogenism is
significantly higher than the mean FSH level in
normoandrogenism.
LH (mIU) 10.58±2.24 7.81±1.85 0.0001 The mean LH level in hyperandrogenism is higher
than the mean LH level in normoandrogenism.
Random Blood
Sugar (mg/ml)
162.8±41.51 114.06±35.30 0.0001 The mean random blood sugar level in
hyperandrogenism is higher than the mean random
blood sugar level in normoandrogenism.
LH/FSH 1.84±0.61 1.42±0.5 0.0001 The mean ratio of LH/FSH in hyperandrogenism is
significantly higher than the mean ratio of LH/FSH in
normoandrogenism.
doi:10.1371/journal.pone.0151510.t001
Table 2. Distribution and comparison of various clinical parameters betweenMTHFR genotypes.
Clinical Parameters Mutant (CT+TT)
(Mean±SD)
Wild type (CC)
(Mean±SD)
Comparison (P-
value)
Inference
Age (years) 30.29±5.08 29.4±5.40 0.44 The mean age in Mutant genotype is similar than the mean age in
Wild genotype.
Height (cm) 151.6±2.84 151.82±2.95 0.69 The mean height in Mutant genotype is almost similar to the mean
height in Wild genotype.
Weight (kg) 76.26±13.3 76.09±14.09 0.95 The mean weight in Mutant genotype is similar than the mean
weight in Wild genotype.
FSH (mIU) 5.37±1.14 5.89±1.13 0.01 The mean FSH level in CC genotype is significantly higher than the
mutant genotype group.
LH (mIU) 9.22±2.51 9.28±2.49 0.91 The mean LH level in Mutant genotype is almost similar than the
mean LH level in Wild genotype.
Random Blood
Sugar (mg/ml)
154.37±55.57 135.66±41.68 0.03 The mean random blood sugar level in Mutant genotype is higher
than the mean random blood sugar level in Wild genotype.
BMI 33.31±5.75 33.34±6.05 0.98 The mean BMI in Mutant genotype is almost similar than the mean
BMI in Wild genotype.
LH/FSH 1.79±0.59 1.59±0.59 0.09 The mean ratio of LH/FSH in Mutant genotype is similar than the
mean ratio of LH/FSH in Wild genotype.
doi:10.1371/journal.pone.0151510.t002
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values remained statistically non-significant for the differences between cases and controls in
each group (Indo-European p = 1, Dravidian p = 0.70). As mentioned above, we sub-grouped
Dravidian patients on the basis of BMI; however, no difference was seen in genotype compari-
son of obese patients versus controls (P = 0.54), non-obese patients versus controls (P = 1.0),
and obese PCOS versus non-obese PCOS patients (P = 0.68).
Meta-analysis
Evaluation of studies. Following the above-mentioned search criteria, we could retrieve
fifteen studies (Fig 1). Out of this, only nine met the inclusion criteria, and the remaining six
were excluded because they were either case reports/reviews or were not case-control studies.
The study by Palep-Singh et al. analyzed the polymorphism in two ethnically different groups;
therefore, it was considered as two data sets. In the study by Idali et al., the two patient groups
were merged because the only difference between them was the criteria followed for the diag-
nosis of PCOS i.e. either by Rotterdam Revised 2003 or by ultrasound. A total of 960 cases and
1028 controls, including those from the present case-control study, were included in the pooled
analysis (Table 3).
Heterogeneity analysis and selection of analysis model. The effect sizes were spread and
appeared to be the part of a normal distribution including an infinite number of studies. This
favored the selection of random effects analysis model. Further, the ‘I2’ value of more than 50%
for between studies comparison showed the presence of true heterogeneity (Pheterogeneity = 0.01,
Q = 23.17, I2 = 56.84, Tau square = 0.18, SE = 0.15,var = 0.02). This further supported the
choice of enrolling random effects model for the overall inference. However, the results of both
the models (fixed and random) have been presented for reference.
Pooled estimate of effect size. Analyses using both fixed effect and random effects models
were undertaken with a priori preference for random effects model due to the expected hetero-
geneity. Analysis using the dominant model of analysis suggested a significant association of
the substitution (CT + TT) with PCOS (p = 0.032, OR = 1.472, 95% CI = 1.035–2.094) (Fig 2).
Outcomes of the TSA were concordant with results of the conventional meta-analysis and
revealed that 677C>T polymorphism was significantly associated with PCOS risk. Moreover,
it also revealed that enough number of samples and studies were included in the meta-analysis
Table 3. Case-control data included in the meta-analysis.
Study Country Race Cases Controls
Total CC CT TT Total CC CT TT
Glueck et al. (1999b) USA Caucasian 41 14 23 4 234 119 89 26
Sills et al. (2001) USA Caucasian 36 25 9 2 18 8 9 1
Tsanadis et al. (2002) Greece Caucasian 30 12 14 4 45 20 19 6
Orio et al. (2003) Italy Caucasian 70 16 41 13 70 17 38 15
Palep-Singh et al. (2007) UK Caucasian 25 11 12 2 16 10 5 1
Palep-Singh et al. (2007) UK Asian 21 14 7 0 9 9 0 0
Choi et al. (2009) Korea Asian 227 67 125 35 115 33 67 15
Karadeniz et al. (2010) Turkey Turkey 86 15 65 6 70 35 28 7
Jain et al. (2012) India Asian 92 76 16 0 95 82 13 0
Idali et al. (2012) Iran Asian 71 36 31 4 100 66 25 9
Present study (2014) Combined India Asian 261 209 49 3 256 209 45 2
Present study (2014) Indo-European Population (IE) India Asian 93 77 16 0 100 83 16 1
Present study (2014) Dravidian Population (D) India Asian 168 132 33 3 156 126 29 1
doi:10.1371/journal.pone.0151510.t003
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to reach a concrete conclusion as the number of samples crossed the O’Brien-Fleming bound-
ary (Fig 3). The cumulative analysis did not show any significant trend in the p value up to the
year 2009; however, beyond Choi et al. (2009), the p value showed a consistent decrease. Analy-
sis using other genetic models did not show association between 677 C>T substitution and
PCOS (Table 4).
The data of all studies, except that of the Asian group of Palep-Singh et al (2007), Choi et al.
(2003) and Idali et al. (2012), fitted well in the Hardy Weinberg equilibrium. Therefore, a sensi-
tivity analysis was conducted after excluding the above three studies. The data were still
Fig 2. Meta-analysis. Forest plot showing the odds ratio, p value and direction of association between MTHFR 677 C>T polymorphism and PCOS. The Z
value shows the degree and direction of the relationship, whereas the P value shows significance of the relationship. The horizontal bar shows the range of
OR with a square in the centre, size of the latter is directly proportional to the weight given to each study. The direction of projection of the horizontal bar
shows the direction of association.
doi:10.1371/journal.pone.0151510.g002
Fig 3. Trail sequence analysis of the studies included in the meta-analysis.
doi:10.1371/journal.pone.0151510.g003
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significantly heterogeneous (Q = 18.26, p = 0.011, I2 = 61.67, Tau square = 0.24, SE = 0.22,
var = 0.048) and the p value turned non-significant (random effects P = 0.089) (Fig 4). There-
fore, we concluded that the studies not following the Hardy Weinberg equilibrium affected the
results of meta-analysis significantly. A careful look into the pooled data showed that the asso-
ciation was ethnic specific. Among all the studies pooled in this analysis, only one study on a
Turkish population reported a highly significant association of 677C>T substitution with
PCOS [18]. We undertook a pooled analysis after its exclusion, which suggested no association
of 677 C>T substitution with PCOS [P = 0.071; OR = 1.28 (0.98–1.67)]. Therefore, 677 C>T
polymorphism seems to be irrelevant to PCOS in most of the populations studied so far, except
in the case of Turkish populations.
Publication bias. Egger’s test showed no evidence of publication bias (B0 = 0.75,
SE = 1.21, 95% CI = -1.98–3.48, two tailed p value = 0.55). Classic fail-safe ‘N’ value of 22 and
Orwin’s fail-safe ‘N’ value of 30, suggested 2.2 and 3 studies, respectively, missing from the
analysis for every study included. Since the possibility of missing so many studies is negligible,
the existence of no bias seems more plausible. Picturesque view of the funnel plot also showed
almost symmetrical distribution of the studies, further ruling out publication bias (Fig 5).
Discussion
Glueck et al. (1999) analyzedMTHFR 677C>T for the first time in 41 PCOS cases and 234
control women, and found no significant difference in the distribution of heterozygous and
homozygous genotypes between cases and controls (P>0.09) [22]. Later, a pilot study
(Cases = 36, Controls = 18) also suggested no association between 677 C>T substitution and
Table 4. Results of meta-analysis (random effects model) using different analysis models.
Model P-value 95% CI Lower Limit Upper Limit
Dominant (CC vs CT+TT) 0.032 1.472 1.035 2.094
Recessive (CT+CC vs TT) 0.389 0.841 0.566 1.248
Co-dominant CC vs. CT 0.115 0.675 0.414 1.101
CC vs. TT 0.520 1.183 0.709 1.975
CT vs. TT 0.070 1.405 0.973 2.029
doi:10.1371/journal.pone.0151510.t004
Fig 4. Sensitivity analysis excluding the studies not fitting the HardyWeinberg equilibrium.
doi:10.1371/journal.pone.0151510.g004
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PCOS risk [19]. Yet another work on 30 cases and 45 controls suggested no significant associa-
tion between this polymorphism and PCOS [21]. Similarly, Orio et al. (2003) after investigation
on 70 Italian patients and an equal number of controls reported no correlation between 677
C>T genotypes and PCOS risk [23]. Palep-Singh et al. (2007) investigated the association
between this substitution and PCOS in Asian (21 cases and 9 controls) and Caucasian study
groups (25 cases and 16 controls) and reported no significant correlation between theMTHFR
genotypes and PCOS [24]. Due to small sample sizes, data generated by the above studies
lacked the power of independent representation. Nevertheless, it is interesting to note that all
the initial studies reported a lack of correlation between the above polymorphism and PCOS
risk. Two genome wide association studies (GWAS) on PCOS have been published; however,
none of them included 677 C>T substitution in the analysis [39,40].
We observed no significant correlation between theMTHFR genotype and PCOS risk in
Indian populations. The two ethnically different groups provided us the opportunity to also
test the effect of ethnicity on PCOS risk. The north Indian populations have an Indo-European
ethnic affinity and are strikingly different from the Dravidian populations [41]. There was no
Fig 5. Funnel plot of precision by log odds ratio showing the absence of publication bias.
doi:10.1371/journal.pone.0151510.g005
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association either in any of the two study groups or in the collective analysis. Classification of
the patients according to the BMI also failed to find any difference between lean/obese cases
and controls. We have used the largest sample size till date and observed no correlation of 677
C>T genotypes with PCOS in Indian populations. Further, no significant difference in homo-
cysteine level between cases and controls ruled out any significance of homocysteine measure-
ment in PCOS cases. Another recent study also reported a lack of association between this
polymorphism and PCOS risk in India [25].
At least three previous meta-analyses have analyzed 677 C>T polymorphism, two of which
stated no correlation [27, 28] while one reported a significant association of the substitution
with PCOS [26]. Bagos (2009) conducted a meta-analysis on six data sets published between
1999 and 2007 and reported no impact of 677 C>T substitution on PCOS risk [28]. A careful
look into this meta-analysis brought forward the problems in data presentation since the values
for homozygous rare and homozygous common genotypes had been interchanged for some of
the studies [28]. Fu et al. (2014) conducted a meta-analysis on nine studies representing 638
cases and 759 controls [26]. The authors reported thatMTHFR 677C>T polymorphism was a
risk factor for PCOS in the dominant model and in CT vs TT comparison. In another meta-
analysis on 607 PCOS and 663 controls from eight studies, Lee et al. (2014) reported that 677
C>T polymorphism was not a risk factor for PCOS [27]. However, none of the meta-analyses
described above undertook a trial sequential analysis, which evaluates a meta-analysis for
power and sample size. We conducted a meta-analysis on 960 cases and 1028 controls and
observed a significant association of 677 C>T substitution with PCOS. Nevertheless, sensitivity
analysis brought forward an interesting observation that the studies showing deviation from
the Hardy Weinberg Equilibrium influenced the results of meta-analysis significantly. Exclu-
sion of these studies suggested a lack of correlation between 677C>T substitution and PCOS.
Among the studies pooled in the analysis, only one study on a Turkish population reported
a significant association of 677C>T substitution with PCOS. In order to analyze for its influ-
ence on meta-analysis, we undertook a pooled analysis after the exclusion of Karadeniz et al.
2010. The exclusion suggested no association of this polymorphism with PCOS. Therefore, 677
C>T polymorphism seems to be unrelated to PCOS in most of the populations studied so far,
except in Turkish populations. This suggests the existence of sensitive studies that influenced
the association of 677 C>T polymorphism with PCOS. Trial sequential analysis showed that
the meta-analysis had enough sample size; however, the overall conclusion was strongly influ-
enced by the sensitive studies. Therefore, further studies need to evaluate the association of this
polymorphism with PCOS in Turkish populations. While genetic risk factors certainly affect
PCOS risk, the end result may a complex outcome of an interplay between genetic and lifestyle
factors such as insulin resistance, obesity and physical inactivity, which can further promote its
occurrence [42]. Eventually, lifestyle modification programmes highlighting the behavioural
management, dietary and exercise interventions have been effective in the general population,
reducing the risk of diabetes and the metabolic syndrome, and have had some initial success in
taming fertility upshots in PCOS [42].
In conclusion, MTHFR 677 C>T genotype does not influence the risk of PCOS in the study
populations and most other populations. Further, the polymorphism is not differently distrib-
uted between obese and non-obese cases, ruling out its correlation with obesity accompanied
PCOS. A direct correlation of 677 C>T polymorphism with PCOS risk was ruled out in two
ethnically different Indian populations. Though meta-analysis suggested 677 C>T substitution
to be a PCOS risk factor, critical analysis of the pooled data suggested that the conclusion was
significantly biased. TSA validated this observation for sufficient sample size and power. There-
fore, we have now reached an adequate sample size for taking a decision regarding the clinical
importance of 677C>T substitution in PCOS cases. Exclusion analysis suggested that the
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association in the meta-analysis was largely due to the study by Karadeniz et al. (2010) on a
Turkish population. The association was skewed due to the studies that deviated from the
Hardy Weinberg equilibrium. Therefore, the exclusion of sensitive studies mentioned above
revealed that 677 substitution has no clinical importance in PCOS. If it affects PCOS risk, the
association is likely to be ethnic-specific and further studies on various populations would pave
the way for identification of ethnic-specific effects. Since the association in Turkish populations
is reported by one study only, further studies on Turkish or ethnically similar populations are
encouraged. Studies on ethnically divergent populations such as East Asians; particularly Chi-
nese and Japanese, may provide new data; nevertheless, there is now sufficient evidence to con-
clude that MTHFR 677 C>T is not clinically important in PCOS in most of the populations.
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